The overall goal of the Penn/Wistar Skin Cancer Development Research Program (DRP) is to advance high quality research, foster new ideas, and to move research studies from pilot to project status. A second goal of the DRP is to create opportunities for the career development of junior faculty or senior investigators who are interested in transitioning into skin cancer research.
Specific aim 1 : To attract, select and fund the most outstanding proposals with significant potential to benefit the Skin Cancer SPORE and translational skin cancer research.
Specific aim 2 : To support and integrate the selected pilot projects into the SPORE program with established processes to review and monitor progress. Women and underrepresented minorities will be strongly encouraged to participate. The DRP has a transparent peer-reviewed selection process that incorporates defined criteria for funding decisions. We require that Developmental Research Awardees be active in SPORE functions, use the SPORE Core resource, and provide formal written progress reports. Within the context of the DRP, we have established high standards and expectations of the investigators and have established a formal process to review and monitor progress of funded pilots. The program measures success by resulting publications, resulting funding, stimulating new aims in existing SPORE projects, and elevation to new full projects for the future.

Public Health Relevance

The Development Research Program of the Penn/Wistar Skin Cancer SPORE will promote translational melanoma and skin cancer research by providing a mechanism for simulating grant applications for pilot projects. The applications go through committee review and with formal procedures for monitoring progress and ensuring integrations within the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA174523-01A1
Application #
8664627
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
Project End
Budget Start
2014-09-15
Budget End
2015-03-31
Support Year
1
Fiscal Year
2014
Total Cost
$73,219
Indirect Cost
$33,641
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504
Duperret, Elizabeth K; Wise, Megan C; Trautz, Aspen et al. (2018) Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Mol Ther 26:435-445
Yuan, Jiao; Hu, Zhongyi; Mahal, Brandon A et al. (2018) Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34:549-560.e9
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Perego, M; Maurer, M; Wang, J X et al. (2018) A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene 37:302-312
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Duperret, Elizabeth K; Trautz, Aspen; Ammons, Dylan et al. (2018) Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice. Clin Cancer Res 24:1190-1201
Hammerlindl, Heinz; Ravindran Menon, Dinoop; Hammerlindl, Sabrina et al. (2018) Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. Clin Cancer Res 24:1090-1102

Showing the most recent 10 out of 89 publications